Standpoint Research downgrades AstraZeneca (NYSE: AZN) from Buy to Hold.

Standpoint analyst says, "The good news from after-the-close on Wednesday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE